Alfaxalone

Verify with FDA CVM →

907 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
907
Total Reports
183
Deaths Reported
2020.0%
Death Rate

Active Ingredients

Alfaxalone

Administration Routes

IntravenousUnknownIntramuscularSubcutaneousParenteralOralTopicalIntraperitonealIntrauterineOphthalmic

Species Affected

Dog 442
Cat 407
Rabbit 22
Unknown 11
Guinea Pig 4
Human 4
Other Reptiles 2
Mouse 2
Lizard 2
Ferret 2

Most Affected Breeds

Domestic Shorthair 205
Unknown 81
Retriever - Labrador 39
Domestic Longhair 39
Chihuahua 34
Dog (unknown) 22
Domestic Mediumhair 21
Cat (other) 20
Cat (unknown) 19
Crossbred Canine/dog 18

Most Reported Reactions

Death 134
Cardiac arrest 74
Bradycardia 71
Lack of efficacy - NOS 59
Vomiting 57
Not eating 57
Hypotension 50
Diarrhoea 49
Tachycardia 48
Apnoea 46
Vocalisation 46
Cyanosis 44

Outcome Breakdown

Recovered/Normal
430 (47.4%)
Ongoing
179 (19.7%)
Died
145 (16.0%)
Outcome Unknown
107 (11.8%)
Euthanized
38 (4.2%)
Recovered with Sequela
9 (1.0%)

Data Summary

Metric Value
Total adverse event reports 907
Reports involving death 183
Case-fatality rate (reported events) 2020.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Alfaxalone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 907 adverse event reports referencing Alfaxalone, including 183 reports in which the animal died — a 2020.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Alfaxalone. Reported administration routes include Intravenous, Unknown, Intramuscular, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Alfaxalone reports are Dog (442 reports), Cat (407 reports), Rabbit (22 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (205), Unknown (81), Retriever - Labrador (39) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Alfaxalone are Death (134), Cardiac arrest (74), Bradycardia (71), Lack of efficacy - NOS (59). Of the 908 reports with a coded outcome, Recovered/Normal is the leading category at 47.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Alfaxalone.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial